Epithelial interferon-stimulated gene programs modulate chemotherapy sensitivity in colorectal cancer via EPSTI1

Although chemotherapy in colorectal cancer (CRC) primarily targets epithelial tumor cells, the epithelial cell-intrinsic mechanisms underlying heterogeneous treatment responses remain poorly understood. We integrated the genomic, transcriptomic, and in vitro drug response profiles of CRC patient-derived tumor organoids (PDTOs) with functional assays to identify epithelial cell-intrinsic determinants of chemotherapy response. An epithelial interferon-stimulated gene (ISG) program, reflecting JAK-STAT pathway activity, was associated with reduced chemosensitivity in PDTOs. Single-cell RNA sequencing data of CRC tumors before and after neoadjuvant chemotherapy showed persistent epithelial ISG expression, with EPSTI1 notably enriched in tumors with incomplete pathological responses. Functional studies demonstrated that EPSTI1 knockdown reduced CRC cell viability and enhanced chemosensitivity. Pharmacologic JAK-STAT inhibition with ruxolitinib suppressed ISG expression and attenuated chemotherapy-induced ISG upregulation. These findings highlight the utility of PDTOs for studying tumor-intrinsic mechanisms of treatment response and identify EPSTI1 as an epithelial modulator of chemosensitivity.

Authors

Institutions

Publication Details

Journal
Oncogene
Published
2026-08-21
DOI
https://doi.org/10.1038/s41388-026-03957-9
Primary Topic
Cancer Cells and Metastasis
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Epithelial interferon-stimulated gene programs modulate chemotherapy sensitivity in colorectal cancer via EPSTI1

Ismaïl Hermelo, Lauri A. Aaltonen, Alfonso Urbanucci, Antti Kurttila et al.
Oncogene
Cancer Cells and Metastasis
article

Epithelial interferon-stimulated gene programs modulate chemotherapy sensitivity in colorectal cancer via EPSTI1

Ismaïl Hermelo, Lauri A. Aaltonen, Alfonso Urbanucci, Antti Kurttila, Laura Renkonen‐Sinisalo, Essi Karjalainen, Tiia Nikupaavola, Emmi Hämäläinen, Matti Nykter, Jukka‐Pekka Mecklin, Ilona Keränen, Erdoğan Pekcan Erkan, Karishma Sajnani, Meiju Kukkonen, Carola Haapamäki, Elina Virolainen, Julia Kolikova, Alli Leppä, Anna Lepisto, Pauli Puolakkainen, Monika Carpelan-Holmström, Laura Koskenvuo, Juha P. Väyrynen, Toni T. Seppälä, Kalle Ojala, iCAN, Timo Tarvainen, Ari Ristimäki, Kornelia Kuc, Selja Koskensalo
article en

Abstract

Although chemotherapy in colorectal cancer (CRC) primarily targets epithelial tumor cells, the epithelial cell-intrinsic mechanisms underlying heterogeneous treatment responses remain poorly understood. We integrated the genomic, transcriptomic, and in vitro drug response profiles of CRC patient-derived tumor organoids (PDTOs) with functional assays to identify epithelial cell-intrinsic determinants of chemotherapy response. An epithelial interferon-stimulated gene (ISG) program, reflecting JAK-STAT pathway activity, was associated with reduced chemosensitivity in PDTOs. Single-cell RNA sequencing data of CRC tumors before and after neoadjuvant chemotherapy showed persistent epithelial ISG expression, with EPSTI1 notably enriched in tumors with incomplete pathological responses. Functional studies demonstrated that EPSTI1 knockdown reduced CRC cell viability and enhanced chemosensitivity. Pharmacologic JAK-STAT inhibition with ruxolitinib suppressed ISG expression and attenuated chemotherapy-induced ISG upregulation. These findings highlight the utility of PDTOs for studying tumor-intrinsic mechanisms of treatment response and identify EPSTI1 as an epithelial modulator of chemosensitivity.

Oncogene
Oslo University Hospital (NO), University of Helsinki (FI), Tampere University of Applied Sciences (FI), Tampere University (FI), Oulu University Hospital (FI), Helsinki University Hospital (FI), Tampere University Hospital (FI), Tampere University (FI), Central Finland Health Care District (FI), University of Jyväskylä (FI), University of Oulu (FI)
Helsingin Yliopisto, Finnish Cancer Institute, Jane ja Aatos Erkon Säätiö, Tays, Syöpäsäätiö, Biocenter Finland, Helsinki Institute of Life Science, Helsingin Yliopisto
Good health and well-being
Openalex Percentile: Top 13%
Cancer Cells and Metastasis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.